MedTrace Logo

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

NCT06526065 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-07-29

No results posted yet for this study

Summary

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Wuerzburg University Hospital

    collaborator OTHER

  • University Hospital Ulm

    collaborator OTHER

  • University of Leipzig

    collaborator OTHER

  • University Hospital Regensburg

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

    collaborator OTHER

  • University of Kiel

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • University Medical Center Goettingen

    lead OTHER

Principal Investigators

  • Lorenz Trümper · PI of the study

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2026-06-01
Completion
2029-06-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06526065 on ClinicalTrials.gov